Please assess the completion status of the following clinical trial:

Trial Title: Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced stage refractory breast cancer~* Progressive or relapsed disease following standard therapy with chemotherapy and/or surgery, and/or radiation~* Patients must have measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions~* Patients must be at least 7 days from last chemotherapy and 30 days from local radiotherapy and/or systemic steroids~* Patients on bisphosphonates, trastuzumab, lapatinib and/or hormonal therapy are eligible~* White blood cell count \>= 1000/ul~* Absolute neutrophil count (ANC) \>= 1200/ul~* Platelets \> 75,000/ul~* Serum creatinine =\< 2.0 mg/dL, a creatinine clearance \> 60 ml/min~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2 X upper limit normal (ULN)~* Total bilirubin \< 2 X ULN~* Patients must have a Performance Status Score (Eastern Cooperative Oncology Group \[ECOG\] Scale) =\< 2~* Patients must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment~* Men and women of reproductive ability must agree to contraceptive use during the study and for 1 month after imiquimod/Abraxane treatment is discontinued~Exclusion Criteria:~* Patients with prior allergic reaction to taxanes~* Patients with any clinically significant active autoimmune disease requiring active treatment with systemic steroids or other immunomodulators~* Pregnant or breast-feeding women~* Patients with peripheral neuropathy \>= Grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (biological therapy, chemo) (Type: EXPERIMENTAL): Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).